Beyond the above-mentioned NLRP3 antagonists already investigated in PD field (at least in pre-clinical studies), other drugs able to inhibit NLRP3 inflammasome with proved good pharmacokinetic profiles and safety and already used for other diseases, might be proposed for clinical trials in PD. This evidence concerns the gene NLRP3 and Parkinson disease.